Table 3:
Summary of immune checkpoint inhibitors studied in the treatment of cervical cancer.
| Drug | Additional Therapy | Mechanism of Action | Trial | Potential Toxicities |
|---|---|---|---|---|
| Pembrolizumab | [monotherapy] | Anti-PD1 | KEYNOTE-15855 | Immune-related side effects: hypophysitis, hepatitis, pneumonitis. Endocrine-related side effects: hypo/hyperthyoridi sm, T1DM |
| carbo/cisplatin | MK-3475–826/KEYNOTE-82657 | |||
| concurrent chemoradiation | 58 | |||
| Nivolumab | [monotherapy] | CHECKMATE 35860 | ||
| Ipilimumab | CHECKMATE 35861 | |||
| [monotherapy] | 62 | |||
| Cemiplimab | [monotherapy] | REGN281063 | ||
| Atezolizumab | cisplatin/paclitaxel/bevacizumab | Anti-PDL1 | 64 | |
| concurrent chemoradiation | 65 | |||
| [monotherapy] | NRG - GY01766 | |||
| Avelumab | valproic acid | 67 | ||
| axitinib | 68 | |||
| Durvalumab | cisplatin/carboplatin | CALLA69 | ||
| tremelimumab + SBRT | 70 | |||
| Ipilimumab | concurrent chemoradiation | Anti-CTLA-4 | 71 | |
| GITR receptor agonist | 72 |
CTLA-4 = Cytotoxic T-lymphocyte-Associated Antigen-4; GITR = Glucocorticoid-Induced TNFR family Related; NCT = National Clinical Trials; PD1 = Programmed Death-1; PDL1 = Programmed Death Ligand-1; SBRT = Stereotatic Body Radiation Therapy; T1DM = Type-1 Diabetes Mellitus; T2DM: Type-2 Diabetes Mellitus.